EBITDA for the second quarter improved by a marginal 0.5% YoY to Rs 1,895 crore. Margins got here in at 25%.
Section-wise, the India enterprise generated Rs 3,146 crore, rising 7% YoY, with the corporate’s model Foracort ranked No. 1 within the home market. The North America enterprise recorded revenues of $233 million, with Albuterol holding the highest place within the general US Albuterol MDI market with a 22% share.
Cipla’s North America enterprise continued to see sturdy traction in key differentiated belongings throughout Q2 FY26. Its Lanreotide product additionally gained share, rising to 22% through the quarter.
The corporate additional strengthened its US portfolio by launching Filgrastim, its first biosimilar within the American market. Moreover, Cipla’s manufacturing facility at Bommasandra, Bengaluru, was labeled as VAI (Voluntary Motion Indicated) by the U.S. FDA through the quarter — a constructive regulatory final result supporting its US operations.
Trying forward, Cipla plans to launch 4 main respiratory belongings by calendar yr 2026, together with gAdvair in This autumn FY26, together with three peptide belongings equivalent to Liraglutide. Notably, three of those 4 respiratory merchandise are being filed from Cipla’s US manufacturing amenities, decreasing regulatory danger and enhancing provide reliability. The Africa phase posted revenues of $134 million, up 5% YoY, with Cipla’s South Africa non-public market enterprise rising at 1.3x the market price. The Rising Markets and Europe phase delivered $110 million, registering 15% YoY development and reaching its highest-ever quarterly income within the area. In branded prescriptions, Cipla maintained its second place within the general continual phase, with the continual combine bettering to 61.8%. Key therapies equivalent to urology, anti-diabetics, cardiac, anti-infectives, and dermatology outpaced market development.
The commerce generics division delivered sturdy development through the quarter, supported by a broader product base. Cipla now has two manufacturers with trailing twelve-month (TTM) income exceeding Rs 100 crore, and 5 manufacturers with TTM income between Rs 50 crore and Rs 100 crore. The corporate additionally launched six new merchandise in Q2 FY26, together with an entry into the orthocare class to develop remedy protection.
In client well being, Cipla reported strong development, with each anchor and transitioned manufacturers scaling up. The enterprise continued its regular EBITDA development trajectory, with flagship merchandise Nicotex, Omnigel, and Cipladine sustaining their No. 1 positions in respective classes.
On Thursday, Cipla shares had been buying and selling marginally greater at Rs 1,582 on the NSE.
